

Thomas Seufferlein

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8740863/publications.pdf>

Version: 2024-02-01

140
papers

6,607
citations

81839

39
h-index

71651

76
g-index

167
all docs

167
docs citations

167
times ranked

11347
citing authors

#	ARTICLE	IF	CITATIONS
1	Trailblazing precision medicine in Europe: A joint view by Genomic Medicine Sweden and the Centers for Personalized Medicine, ZPM, in Germany. <i>Seminars in Cancer Biology</i> , 2022, 84, 242-254.	4.3	22
2	The Selective 5-HT1A Agonist SR57746A Protects Intestinal Epithelial Cells and Enteric Glia Cells and Promotes Mucosal Recovery in Experimental Colitis. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 423-433.	0.9	4
3	Functional Genomic Screening in Human Pluripotent Stem Cells Reveals New Roadblocks in Early Pancreatic Endoderm Formation. <i>Cells</i> , 2022, 11, 582.	1.8	2
4	Organoids at the PUB: The Porcine Urinary Bladder Serves as a Pancreatic Niche for Advanced Cancer Modeling. <i>Advanced Healthcare Materials</i> , 2022, 11, e2102345.	3.9	7
5	Green Tea Extract to Prevent Colorectal Adenomas, Results of a Randomized, Placebo-Controlled Clinical Trial. <i>American Journal of Gastroenterology</i> , 2022, 117, 884-894.	0.2	18
6	Digestive cancer screening across Europe. <i>United European Gastroenterology Journal</i> , 2022, 10, 435-437.	1.6	8
7	Drug Inhibition of SARS-CoV-2 Replication in Human Pluripotent Stem Cellâ€Derived Intestinal Organoids. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2021, 11, 935-948.	2.3	69
8	Nintedanib plus <scp>mFOLFOX6</scp> as secondâ€line treatment of metastatic, chemorefractory colorectal cancer: The randomised, placeboâ€controlled, phase <scp>II TRICCâ€C</scp> study (<scp>AIOâ€KRK</scp>â€0111). <i>International Journal of Cancer</i> , 2021, 148, 1428-1437.	2.3	2
9	Synergistic targeting and resistance to PARP inhibition in DNA damage repair-deficient pancreatic cancer. <i>Gut</i> , 2021, 70, 743-760.	6.1	49
10	Aseptic Liver Abscesses as an Exceptional Finding in Coganâ€™s Syndrome. <i>Hepatology</i> , 2021, 73, 2067-2070.	3.6	2
11	DNA damage repair as a target in pancreatic cancer: state-of-the-art and future perspectives. <i>Gut</i> , 2021, 70, 606-617.	6.1	108
12	Perspective on mHealth Concepts to Ensure Usersâ€™ Empowermentâ€From Adverse Event Tracking for COVID-19 Vaccinations to Oncological Treatment. <i>IEEE Access</i> , 2021, 9, 83863-83875.	2.6	8
13	Enteropathogenic Infections: Organoids Go Bacterial. <i>Stem Cells International</i> , 2021, 2021, 1-14.	1.2	7
14	RINT1 Regulates SUMOylation and the DNA Damage Response to Preserve Cellular Homeostasis in Pancreatic Cancer. <i>Cancer Research</i> , 2021, 81, 1758-1774.	0.4	6
15	SARS-CoV-2 infects and replicates in cells of the human endocrine and exocrine pancreas. <i>Nature Metabolism</i> , 2021, 3, 149-165.	5.1	378
16	A Follow-Up Study of a European IgG4-Related Disease Cohort Treated with Rituximab. <i>Journal of Clinical Medicine</i> , 2021, 10, 1329.	1.0	17
17	Association between miRNA signatures in serum samples from epidermal growth factor inhibitor treated patients and skin toxicity. <i>Oncotarget</i> , 2021, 12, 982-995.	0.8	0
18	A Prospective Feasibility Trial to Challenge Patientâ€™Derived Pancreatic Cancer Organoids in Predicting Treatment Response. <i>Cancers</i> , 2021, 13, 2539.	1.7	26

#	ARTICLE	IF	CITATIONS
19	Modeling plasticity and dysplasia of pancreatic ductal organoids derived from human pluripotent stem cells. <i>Cell Stem Cell</i> , 2021, 28, 1105-1124.e19.	5.2	53
20	Patient Empowerment During the COVID-19 Pandemic by Ensuring Safe and Fast Communication of Test Results: Implementation and Performance of a Tracking System. <i>Journal of Medical Internet Research</i> , 2021, 23, e27348.	2.1	6
21	Single-cell-resolved differentiation of human induced pluripotent stem cells into pancreatic duct-like organoids on a microwell chip. <i>Nature Biomedical Engineering</i> , 2021, 5, 897-913.	11.6	61
22	Small Extracellular Vesicles and Metastasis—Blame the Messenger. <i>Cancers</i> , 2021, 13, 4380.	1.7	11
23	Pancreatic Cancer Small Extracellular Vesicles (Exosomes): A Tale of Short- and Long-Distance Communication. <i>Cancers</i> , 2021, 13, 4844.	1.7	15
24	Systemic Therapy for Metastatic Pancreatic Cancer. <i>Current Treatment Options in Oncology</i> , 2021, 22, 106.	1.3	33
25	Mutations and variants of ONECUT1 in diabetes. <i>Nature Medicine</i> , 2021, 27, 1928-1940.	15.2	24
26	CDKN2A-Mutated Pancreatic Ductal Organoids from Induced Pluripotent Stem Cells to Model a Cancer Predisposition Syndrome. <i>Cancers</i> , 2021, 13, 5139.	1.7	15
27	Etiology and Morphology Impact on the Clinical Course of Chronic Pancreatitis. <i>Digestion</i> , 2021, 102, 462-468.	1.2	0
28	Small Extracellular Vesicles Propagate the Inflammatory Response After Trauma. <i>Advanced Science</i> , 2021, 8, e2102381.	5.6	12
29	COVID-19 and digestive health: Implications for prevention, care and the use of COVID-19 vaccines in vulnerable patients. <i>United European Gastroenterology Journal</i> , 2021, 9, 1091-1095.	1.6	8
30	Transcriptional changes and the role of ONECUT1 in hPSC pancreatic differentiation. <i>Communications Biology</i> , 2021, 4, 1298.	2.0	16
31	Differentiation of human pluripotent stem cells into pancreatic duct-like organoids. <i>STAR Protocols</i> , 2021, 2, 100913.	0.5	13
32	Transcutaneous carbon dioxide monitoring as a valid complementary method in acute respiratory failure. <i>European Respiratory Journal</i> , 2020, 56, 2002137.	3.1	0
33	Maintenance Therapy for ATM-Deficient Pancreatic Cancer by Multiple DNA Damage Response Interferences after Platinum-Based Chemotherapy. <i>Cells</i> , 2020, 9, 2110.	1.8	17
34	An Immunological Glance on Pancreatic Ductal Adenocarcinoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3345.	1.8	14
35	Pancreatic cancer-derived organoids “a disease modeling tool to predict drug response. <i>United European Gastroenterology Journal</i> , 2020, 8, 594-606.	1.6	48
36	A tumor-specific neoepitope expressed in homologous/self or heterologous/viral antigens induced comparable effector CD8+ T-cell responses by DNA vaccination. <i>Vaccine</i> , 2020, 38, 3711-3719.	1.7	9

#	ARTICLE	IF	CITATIONS
37	Protein Kinase D1, Reduced in Human Pancreatic Tumors, Increases Secretion of Small Extracellular Vesicles From Cancer Cells That Promote Metastasis to Lung in Mice. <i>Gastroenterology</i> , 2020, 159, 1019-1035.e22.	0.6	47
38	Green tea extract to prevent colorectal adenomas in men and women: Results of the MIRACLE trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 1551-1551.	0.8	0
39	Novel Concepts in the Management of Colorectal Cancer. <i>Visceral Medicine</i> , 2019, 35, 245-246.	0.5	0
40	Molecular Approaches to Metastatic Colorectal Cancer: Better Diagnosis “ Better Treatment?. <i>Visceral Medicine</i> , 2019, 35, 259-265.	0.5	5
41	MEK Inhibition Targets Cancer Stem Cells and Impedes Migration of Pancreatic Cancer Cells<i>In Vitro</i>and<i>In Vivo</i>. <i>Stem Cells International</i> , 2019, 2019, 1-11.	1.2	11
42	An IKK/NF- κ B Activation/p53 Deletion Sequence Drives Liver Carcinogenesis and Tumor Differentiation. <i>Cancers</i> , 2019, 11, 1410.	1.7	4
43	Endogenously Expressed Antigens Bind Mammalian RNA via Cationic Domains that Enhance Priming of Effector CD8 α T Cells by DNA Vaccination. <i>Molecular Therapy</i> , 2019, 27, 661-672.	3.7	12
44	Pancreatic Ductal Organoids React Kras Dependent to the Removal of Tumor Suppressive Roadblocks. <i>Stem Cells International</i> , 2019, 2019, 1-8.	1.2	2
45	Optimizing the management of locally advanced pancreatic cancer with a focus on induction chemotherapy: Expert opinion based on a review of current evidence. <i>Cancer Treatment Reviews</i> , 2019, 77, 1-10.	3.4	48
46	Effect of a Single Aspirin Dose Prior to Fecal Immunochemical Testing on Test Sensitivity for Detecting Advanced Colorectal Neoplasms. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 1686.	3.8	22
47	A Blood-Based Multi Marker Assay Supports the Differential Diagnosis of Early-Stage Pancreatic Cancer. <i>Theranostics</i> , 2019, 9, 1280-1287.	4.6	45
48	Treatment of pancreatic cancer“neoadjuvant treatment in resectable pancreatic cancer (PDAC). <i>Translational Gastroenterology and Hepatology</i> , 2019, 4, 21-21.	1.5	42
49	Tumor-associated macrophage-secreted 14-3-3 η signals via AXL to promote pancreatic cancer chemoresistance. <i>Oncogene</i> , 2019, 38, 5469-5485.	2.6	57
50	Endoscopic surveillance after surgical or endoscopic resection for colorectal cancer: European Society of Gastrointestinal Endoscopy (ESGE) and European Society of Digestive Oncology (ESDO) Guideline. <i>Endoscopy</i> , 2019, 51, 266-277.	1.0	45
51	Endoscopic surveillance after surgical or endoscopic resection for colorectal cancer: European Society of Gastrointestinal Endoscopy (ESGE) and European Society of Digestive Oncology (ESDO) Guideline. <i>Endoscopy</i> , 2019, 51, C1-C1.	1.0	13
52	Concerted regulation of actin polymerization during constitutive secretion by Cortactin and PKD2. <i>Journal of Cell Science</i> , 2019, 132, .	1.2	9
53	Systemic treatment of pancreatic cancer revisited. <i>Seminars in Oncology</i> , 2019, 46, 28-38.	0.8	81
54	Genetic Biopsy for Prediction of Surveillance Intervals after Endoscopic Resection of Colonic Polyps: Results of the GENESIS Study. <i>United European Gastroenterology Journal</i> , 2018, 6, 290-299.	1.6	8

#	ARTICLE	IF	CITATIONS
55	PKD regulates actin polymerization, neutrophil deformability, and transendothelial migration in response to fMLP and trauma. <i>Journal of Leukocyte Biology</i> , 2018, 104, 615-630.	1.5	11
56	CabaCast: multicentre, Phase II study with cabazitaxel in previously treated patients with advanced or metastatic adenocarcinoma of the esophagogastric junction and stomach. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 559-569.	1.2	5
57	Protein kinase D2: a versatile player in cancer biology. <i>Oncogene</i> , 2018, 37, 1263-1278.	2.6	20
58	ECCO essential requirements for quality cancer care: Oesophageal and gastric cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 122, 179-193.	2.0	57
59	Barriers and Facilitating Factors for Research Involvement in Cancer Centers. <i>Cancer Control</i> , 2018, 25, 107327481876547.	0.7	4
60	Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group. <i>BMC Cancer</i> , 2018, 18, 1298.	1.1	63
61	YAP Activation Drives Liver Regeneration after Cholestatic Damage Induced by Rbpj Deletion. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3801.	1.8	20
62	Time trends in dyspepsia and association with H. pylori and work-related stress – An observational study in white collar employees in 1996 and 2015. <i>PLoS ONE</i> , 2018, 13, e0199533.	1.1	4
63	Organoidomics – falling star or new galaxy in pancreatic cancer?. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018, 15, 586-587.	8.2	5
64	Regorafenib. <i>Recent Results in Cancer Research</i> , 2018, 211, 45-56.	1.8	100
65	Population nutrigenetics of green tea extract. <i>PLoS ONE</i> , 2018, 13, e0193074.	1.1	51
66	Targeted deep sequencing of circulating tumor DNA in metastatic pancreatic cancer. <i>Oncotarget</i> , 2018, 9, 2076-2085.	0.8	42
67	Human pluripotent stem cell-derived acinar/ductal organoids generate human pancreas upon orthotopic transplantation and allow disease modelling. <i>Gut</i> , 2017, 66, 473-486.	6.1	174
68	Differential regulation of PKD isoforms in oxidative stress conditions through phosphorylation of a conserved Tyr in the P+1 loop. <i>Scientific Reports</i> , 2017, 7, 887.	1.6	15
69	3rd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of pancreatic cancer. <i>European Journal of Cancer</i> , 2017, 79, 41-49.	1.3	43
70	Intermediate filament reorganization dynamically influences cancer cell alignment and migration. <i>Scientific Reports</i> , 2017, 7, 45152.	1.6	24
71	ECCO Essential Requirements for Quality Cancer Care: Colorectal Cancer. A critical review. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 110, 81-93.	2.0	54
72	Clinical relevance of molecular diagnostics in gastrointestinal (GI) cancer: European Society of Digestive Oncology (ESDO) expert discussion and recommendations from the 17th European Society for Medical Oncology (ESMO)/World Congress on Gastrointestinal Cancer, Barcelona. <i>European Journal of Cancer</i> , 2017, 86, 305-317.	1.3	22

#	ARTICLE	IF	CITATIONS
73	ATM Deficiency Generating Genomic Instability Sensitizes Pancreatic Ductal Adenocarcinoma Cells to Therapy-Induced DNA Damage. <i>Cancer Research</i> , 2017, 77, 5576-5590.	0.4	94
74	The armadillo protein p0071 controls KIF3 motor transport. <i>Journal of Cell Science</i> , 2017, 130, 3374-3387.	1.2	7
75	Improving Outcomes in Patients with CRC: The Role of Patient Reported Outcomes – An ESDO Report. <i>Cancers</i> , 2017, 9, 59.	1.7	5
76	Shifting cancer care towards Multidisciplinarity: the cancer center certification program of the German cancer society. <i>BMC Cancer</i> , 2017, 17, 850.	1.1	68
77	Treatment monitoring in metastatic colorectal cancer patients by quantification and KRAS genotyping of circulating cell-free DNA. <i>PLoS ONE</i> , 2017, 12, e0174308.	1.1	40
78	Predictive blood plasma biomarkers for EGFR inhibitor-induced skin rash. <i>Oncotarget</i> , 2017, 8, 35193-35204.	0.8	10
79	STK33 participates to HSP90-supported angiogenic program in hypoxic tumors by regulating HIF-1 α /VEGF signaling pathway. <i>Oncotarget</i> , 2017, 8, 77474-77488.	0.8	17
80	Pluripotency Factors on Their Lineage Move. <i>Stem Cells International</i> , 2016, 2016, 1-16.	1.2	12
81	Imaging in Colorectal Cancer: Progress and Challenges for the Clinicians. <i>Cancers</i> , 2016, 8, 81.	1.7	61
82	The role of pluripotency factors to drive stemness in gastrointestinal cancer. <i>Stem Cell Research</i> , 2016, 16, 349-357.	0.3	76
83	Cortactin is a scaffolding platform for the E-Cadherin adhesion complex controlled by protein kinase D1 phosphorylation. <i>Journal of Cell Science</i> , 2016, 129, 2416-29.	1.2	15
84	Dosing to rash? – The role of erlotinib metabolic ratio from patient serum in the search of predictive biomarkers for EGFR inhibitor-mediated skin rash. <i>European Journal of Cancer</i> , 2016, 55, 131-139.	1.3	19
85	Chemoradiotherapy, the backbone of radiotherapy in gastrointestinal oncology. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2016, 30, 511-513.	1.0	2
86	Mass spectrometry-based secretome analysis of non-small cell lung cancer cell lines. <i>Proteomics</i> , 2016, 16, 2801-2814.	1.3	14
87	Tbx3 fosters pancreatic cancer growth by increased angiogenesis and activin/nodal-dependent induction of stemness. <i>Stem Cell Research</i> , 2016, 17, 367-378.	0.3	27
88	Esophageal stenting for benign and malignant disease: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline. <i>Endoscopy</i> , 2016, 48, 939-948.	1.0	257
89	Pancreatic cancer chemoradiotherapy. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2016, 30, 617-628.	1.0	11
90	Radiation therapy in cholangiocellular carcinomas. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2016, 30, 593-602.	1.0	16

#	ARTICLE	IF	CITATIONS
91	Detection of Hot-Spot Mutations in Circulating Cell-Free DNA From Patients With Intraductal Papillary Mucinous Neoplasms of the Pancreas. <i>Gastroenterology</i> , 2016, 151, 267-270.	0.6	76
92	DocOx (AIO-PK0106): a phase II trial of docetaxel and oxaliplatin as a second line systemic therapy in patients with advanced pancreatic ductal adenocarcinoma. <i>BMC Cancer</i> , 2016, 16, 21.	1.1	16
93	PKM2 promotes tumor angiogenesis by regulating HIF-1 α through NF- κ B activation. <i>Molecular Cancer</i> , 2016, 15, 3.	7.9	233
94	Precision medicine in pancreatic cancer – fact or fiction?. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2016, 13, 74-75.	8.2	26
95	Awareness, Understanding, and Adoption of Precision Medicine to Deliver Personalized Treatment for Patients With Cancer: A Multinational Survey Comparison of Physicians and Patients. <i>Oncologist</i> , 2016, 21, 292-300.	1.9	40
96	A rare cause of upper GI bleeding and wasting disease. <i>Gut</i> , 2016, 65, 787-787.	6.1	0
97	Protein Kinase D2 Assembles a Multiprotein Complex at the Trans-Golgi Network to Regulate Matrix Metalloproteinase Secretion. <i>Journal of Biological Chemistry</i> , 2016, 291, 462-477.	1.6	39
98	Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. <i>Lancet, The</i> , 2016, 387, 545-557.	6.3	878
99	Open Surgical versus Minimal Invasive Necrosectomy of the Pancreas – A Retrospective Multicenter Analysis of the German Pancreatitis Study Group. <i>PLoS ONE</i> , 2016, 11, e0163651.	1.1	37
100	The occurrence of mutant KRAS clones in the blood of RAS wild type colorectal cancer patients: Impact of response or failure under anti-EGFR therapy.. <i>Journal of Clinical Oncology</i> , 2016, 34, 600-600.	0.8	0
101	Surveillance after curative resection of pancreatic ductal adenocarcinoma: A multicenter survey in Germany.. <i>Journal of Clinical Oncology</i> , 2016, 34, e15713-e15713.	0.8	0
102	IGF1 drives chromogranin A secretion via activation of Arf1 in human neuroendocrine tumour cells. <i>Journal of Cellular and Molecular Medicine</i> , 2015, 19, 948-959.	1.6	7
103	Colorectal cancer. <i>Nature Reviews Disease Primers</i> , 2015, 1, 15065.	18.1	1,104
104	A Dynamic Role of TBX3 in the Pluripotency Circuitry. <i>Stem Cell Reports</i> , 2015, 5, 1155-1170.	2.3	57
105	Trans-sectoral care in patients with colorectal cancer: Protocol of the randomized controlled multi-center trial Supportive Cancer Care Networkers (SCAN). <i>BMC Cancer</i> , 2015, 15, 997.	1.1	6
106	Comparison of Acoustic Structure Quantification (ASQ), shearwave elastography and histology in patients with diffuse hepatopathies. <i>BMC Medical Imaging</i> , 2015, 15, 58.	1.4	17
107	PRKD2: A two-pronged kinase crucial for the tumor-supporting activity of HSP90. <i>Molecular and Cellular Oncology</i> , 2015, 2, e981444.	0.3	6
108	Loss of ATM accelerates pancreatic cancer formation and epithelial–mesenchymal transition. <i>Nature Communications</i> , 2015, 6, 7677.	5.8	90

#	ARTICLE	IF	CITATIONS
109	A time frame permissive for Protein Kinase D2 activity to direct angiogenesis in mouse embryonic stem cells. <i>Scientific Reports</i> , 2015, 5, 11742.	1.6	7
110	A Fresh Look on T-Box Factor Action in Early Embryogenesis (T-Box Factors in Early Development). <i>Stem Cells and Development</i> , 2015, 24, 1833-1851.	1.1	9
111	High-throughput screening identified inherited genetic variations in the EGFR pathway contributing to skin toxicity of EGFR inhibitors. <i>Pharmacogenomics</i> , 2015, 16, 1605-1619.	0.6	7
112	ACCEPT: Afatinib as cancer therapy for exocrine pancreatic tumors – An explorative randomized phase II trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS4150-TPS4150.	0.8	2
113	DocOx (AIO-PK0106): A phase II trial with docetaxel and oxaliplatin as a second-line systemic therapy for patients with advanced and/or metastatic adenocarcinoma of the pancreas – Final results.. <i>Journal of Clinical Oncology</i> , 2015, 33, 352-352.	0.8	1
114	The MIRACLE trial: A randomized, controlled trial comparing green tea extract versus placebo for the prevention of metachronous colon adenomas in a screening population.. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS786-TPS786.	0.8	1
115	Self-Expandable Metal Stents for Persisting Esophageal Variceal Bleeding after Band Ligation or Injection-Therapy: A Retrospective Study. <i>PLoS ONE</i> , 2015, 10, e0126525.	1.1	17
116	Neonax (AIO-PAK-0313): Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer: A phase II study of the AIO Pancreatic Cancer Group.. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS497-TPS497.	0.8	2
117	DocOx (AIO-PK0106): A phase II trial with docetaxel and oxaliplatin as a second-line systemic therapy for patients with advanced and/or metastatic adenocarcinoma of the pancreas – Final results.. <i>Journal of Clinical Oncology</i> , 2015, 33, 4122-4122.	0.8	0
118	Protein Kinase D family kinases. <i>Bioarchitecture</i> , 2014, 4, 111-115.	1.5	10
119	HSP90 Supports Tumor Growth and Angiogenesis through PRKD2 Protein Stabilization. <i>Cancer Research</i> , 2014, 74, 7125-7136.	0.4	52
120	Protein kinase D2 induces invasion of pancreatic cancer cells by regulating matrix metalloproteinases. <i>Molecular Biology of the Cell</i> , 2014, 25, 324-336.	0.9	49
121	Cytokine regulation by epidermal growth factor receptor inhibitors and epidermal growth factor receptor inhibitor associated skin toxicity in cancer patients. <i>European Journal of Cancer</i> , 2014, 50, 1855-1863.	1.3	46
122	Pancreatic Cancer: Progress in Systemic Therapy. <i>Gastrointestinal Tumors</i> , 2014, 1, 167-179.	0.3	11
123	Regorafenib. <i>Recent Results in Cancer Research</i> , 2014, 201, 185-196.	1.8	22
124	NEONAX: Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer – A phase II study of the AIO Pancreatic Cancer Group.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS4158-TPS4158.	0.8	7
125	Systemic treatment of advanced pancreatic cancer – step by step progress. <i>Gut</i> , 2013, 62, 660-661.	6.1	3
126	Recruitment of arfaptins to the trans-Golgi network by PI(4)P and their involvement in cargo export. <i>EMBO Journal</i> , 2013, 32, 1717-1729.	3.5	61

#	ARTICLE	IF	CITATIONS
127	Different Regulation of Physiological and Tumor Angiogenesis in Zebrafish by Protein Kinase D1 (PKD1). PLoS ONE, 2013, 8, e68033.	1.1	18
128	DOCOX: A phase II trial with docetaxel and oxaliplatin as a second-line systemic therapy for patients with advanced and/or metastatic adenocarcinoma of the pancreas.. Journal of Clinical Oncology, 2013, 31, 4034-4034.	0.8	2
129	Protein Kinase D1 Mediates Anchorage-dependent and -independent Growth of Tumor Cells via the Zinc Finger Transcription Factor Snail1. Journal of Biological Chemistry, 2012, 287, 32367-32380.	1.6	35
130	Role of the Second Cysteine-rich Domain and Pro275 in Protein Kinase D2 Interaction with ADP-Ribosylation Factor 1, <i>Trans</i>-Golgi Network Recruitment, and Protein Transport. Molecular Biology of the Cell, 2010, 21, 1011-1022.	0.9	57
131	Characterization of cortactin as an in vivo protein kinase D substrate: Interdependence of sites and potentiation by Src. Cellular Signalling, 2009, 21, 253-263.	1.7	24
132	Tumor biology and cancer therapy “an evolving relationship. Cell Communication and Signaling, 2009, 7, 19.	2.7	11
133	Protein kinase D2 regulates chromogranin A secretion in human BON neuroendocrine tumour cells. Cellular Signalling, 2008, 20, 925-934.	1.7	21
134	Regulation of cyclin D1 expression by autocrine IGF-I in human BON neuroendocrine tumour cells. Oncogene, 2005, 24, 1284-1289.	2.6	38
135	From Tumorigenesis to Tumor Progression: Signaling Pathways Driving Tumor Invasion and Metastasis. , 2005, , 299-339.		3
136	Protein kinase D regulates basolateral membrane protein exit from trans-Golgi network. Nature Cell Biology, 2004, 6, 106-112.	4.6	225
137	Evidence for radiosensitizing by gliotoxin in HL-60 cells: implications for a role of NF- κ B independent mechanisms. Oncogene, 2003, 22, 8786-8796.	2.6	7
138	Protein kinase D: a family affair. FEBS Letters, 2003, 546, 81-86.	1.3	198
139	The impact of pharmacogenomics on gastrointestinal cancer therapy. Pharmacogenomics, 2002, 3, 625-633.	0.6	4
140	Which EORTC QLQ-C30 and -CR29 scores are relevant for clinicians for therapy planning and decisions?. Coloproctology, 0, , 1.	0.3	1